BNC210 data demonstrates improved efficacy and faster recovery levels: BNC210 has demonstrated efficacy in the contextual fear-conditioning extinction paradigm in C56BL6 mice where it significantly enhanced fear extinction, reducing fear behavior, while diazepam (Valium) demonstrated an inhibitory effect resulting in prolonged fear behavior. In humans, BNC210 treatment reduced the emotional impact of a CCK-4 induced panic attack. Individuals who suffered an induced panic attack, and to whom BNC210 was administered, showed faster recovery following their unpleasant physical and emotional experience, compared to placebo. The data continues to demonstrate BNC210 is a potent anxiolytic compound with equivalent acute efficacy to benzodiazepines with anti-depressant properties and few side effects. Notably, it highlights the potential of BNC210 as a novel treatment for patients who are suffering with GAD and other anxiety related disorders and suggests a role for BNC210 in the treatment of stress and trauma related disorders.